EFI Lake Geneva Ventures

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Hylomorph is a MedTech company that develops biomaterial solutions to improve the interface between implantable medical devices and biological tissue. Its technology includes a cellulose film designed to prevent fibrotic encapsulation and adhesion, helping to reduce postoperative complications such as fibrosis, infection, and device migration, thereby aiming to lower implant failure. The approach combines biotech with surface micro-engineering to optimize tissue implant interaction. First indications target cardiac devices like pacemakers and defibrillators, as well as neurostimulators. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Seprify is a manufacturer specializing in cellulose-based white pigments designed to replace titanium dioxide in various applications. The company's innovative pigments are derived from renewable materials that are cost-effective, biocompatible, and easily processed. By offering sustainable solutions, Seprify enables businesses across multiple industries, including paints, inks, cosmetics, pharmaceuticals, and food, to create safer and more environmentally friendly products. With a vision for a circular economy, Seprify aims to cater to the growing demand for sustainable materials in the marketplace.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Terapet SA is a Switzerland-based company founded in 2019 at CERN by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals. The company specializes in developing advanced proton therapy technology for cancer treatment, which allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This innovative approach leverages the unique properties of protons, which stop at a predetermined depth within the patient, enabling the delivery of a concentrated dose to the tumor. Terapet's system also provides real-time, three-dimensional monitoring of the proton dose administered, enhancing treatment accuracy and safety. With a focus on making cutting-edge cancer therapy more accessible and cost-effective, Terapet is preparing for the market launch of its initial product.